Zacks: Brokerages Expect Pharming Group (PHGUF) Will Announce Quarterly Sales of $18.76 Million
Brokerages expect Pharming Group (NASDAQ:PHGUF) to announce sales of $18.76 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Pharming Group’s earnings. The highest sales estimate is $19.32 million and the lowest is $18.19 million. The business is expected to issue its next quarterly earnings results on Thursday, October 26th.
On average, analysts expect that Pharming Group will report full year sales of $18.76 million for the current year, with estimates ranging from $72.04 million to $75.45 million. For the next year, analysts anticipate that the firm will report sales of $100.91 million per share, with estimates ranging from $85.26 million to $109.77 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Pharming Group.
Separately, Zacks Investment Research downgraded Pharming Group from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th.
Pharming Group (NASDAQ:PHGUF) traded up 3.610329% during mid-day trading on Friday, hitting $0.872917. The stock had a trading volume of 626,814 shares. The stock’s market capitalization is $441.36 million. Pharming Group has a one year low of $0.18 and a one year high of $0.87.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/02/zacks-brokerages-expect-pharming-group-phguf-will-announce-quarterly-sales-of-18-76-million.html.
About Pharming Group
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related stocks with our FREE daily email newsletter.